Zoniporide hydrochloride hydrate

Zoniporide hydrochloride hydrate Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Beijing Jin Ming Biotechnology Co., Ltd.  
Tel: 010-60605840
Email: psaitong@jm-bio.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: RD International Technology Co., Limited  
Tel: 18024082417
Email: market@ubiochem.com

Zoniporide hydrochloride hydrate manufacturers

Zoniporide hydrochloride hydrate Basic information
Product Name:Zoniporide hydrochloride hydrate
Synonyms:CP-597396 hydrochloride hydrate
CAS:863406-85-3
MF:C17H19ClN6O2
MW:374.83
EINECS:
Product Categories:
Mol File:863406-85-3.mol
Zoniporide hydrochloride hydrate Structure
Zoniporide hydrochloride hydrate Chemical Properties
storage temp. Store at -20°C
solubility Soluble in DMSO
form Solid
color White to off-white
Safety Information
MSDS Information
Zoniporide hydrochloride hydrate Usage And Synthesis
UsesZoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM)[1][2].
in vivo

Zoniporide hydrochloride hydrate (0.25-4 mg/kg; i.v.; every hour for 2 hours) elicits a dose-dependent reduction in infarct size (ED50=0.45 mg/kg/h) in open chest anesthetized rabbits[1].
Zoniporide exhibits moderate plasma protein binding, has a t1/2 of 1.5 hours in monkeys, and has one major active metabolite[1].
Zoniporide hydrochloride hydrate treatment shows the AUC0-∞ and t1/2 are 0.07 μg h/mL and 0.5 hours, respectively[2].

Animal Model:Rabbit[1]
Dosage:0.25, 1, 4 mg/kg
Administration:Every hour for 2 hours; intravenous injection
Result:Elicited a significant dose-dependent reduction in infarct size in the anesthetized rabbit. The ED50 was 0.45 mg/kg/h.
Animal Model:Rat[2]
Dosage:1 mg/kg
Administration:Intravenous injection(Pharmacokinetic Analysis)
Result:The AUC0-∞ and t1/2 were 0.07 μg h/mL and 0.5 hours, respectively.
References[1] Tracey WR, et al. Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. DOI:10.1111/j.1527-3466.2003.tb00103.x
[2] Guzman-Perez A, et al. Discovery of zoniporide: a potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. Bioorg Med Chem Lett. 2001 Mar 26;11(6):803-7. DOI:10.1016/s0960-894x(01)00059-2
Zoniporide hydrochloride hydrate Preparation Products And Raw materials
Tag:Zoniporide hydrochloride hydrate(863406-85-3) Related Product Information
Zoniporide Hydrochloride ZONIPORIDE Ziprasidone Hydrochloride Zoniporide dihydrochloride BIIB 513 BMS-284640